Dr. Victor T. Lin
Claim this profileMary Bird Perkins Cancer Center
Area of expertise
Lung Cancer
Victor T. Lin has run 12 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Victor T. Lin has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Mary Bird Perkins Cancer Center
Louisiana Hematology Oncology Associates LLC
Clinical Trials Victor T. Lin is currently running
Olomorasib
for Non-Small Cell Lung Cancer
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Recruiting
1 award
Phase 3
8 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting
1 award
N/A
10 criteria
More about Victor T. Lin
Clinical Trial Related
1 year of experience running clinical trials · Led 41 trials as a Principal Investigator · 22 Active Clinical Trials
Treatments Victor T. Lin has experience with
- Pembrolizumab
- Cisplatin
- Fluorouracil
- Atezolizumab
- Gemcitabine Hydrochloride
- Nivolumab
Breakdown of trials Victor T. Lin has run
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Victor T. Lin specialize in?
Victor T. Lin focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Victor T. Lin currently recruiting for clinical trials?
Yes, Victor T. Lin is currently recruiting for 22 clinical trials in Baton Rouge Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Victor T. Lin has studied deeply?
Yes, Victor T. Lin has studied treatments such as Pembrolizumab, Cisplatin, Fluorouracil.
What is the best way to schedule an appointment with Victor T. Lin?
Apply for one of the trials that Victor T. Lin is conducting.
What is the office address of Victor T. Lin?
The office of Victor T. Lin is located at: Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana 70809 United States. This is the address for their practice at the Mary Bird Perkins Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.